Free Trial
NASDAQ:INO

Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

Inovio Pharmaceuticals logo
$2.04 -0.07 (-3.32%)
As of 04:00 PM Eastern

About Inovio Pharmaceuticals Stock (NASDAQ:INO)

Key Stats

Today's Range
$2.02
$2.18
50-Day Range
$1.71
$2.27
52-Week Range
$1.42
$12.33
Volume
907,444 shs
Average Volume
639,868 shs
Market Capitalization
$74.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.75
Consensus Rating
Moderate Buy

Company Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

INO MarketRank™: 

Inovio Pharmaceuticals scored higher than 73% of companies evaluated by MarketBeat, and ranked 281st out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Inovio Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Inovio Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($4.23) to ($2.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inovio Pharmaceuticals is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inovio Pharmaceuticals is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Inovio Pharmaceuticals has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Inovio Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    17.75% of the float of Inovio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inovio Pharmaceuticals has recently decreased by 1.67%, indicating that investor sentiment is improving.
  • Dividend Yield

    Inovio Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Inovio Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.75% of the float of Inovio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inovio Pharmaceuticals has recently decreased by 1.67%, indicating that investor sentiment is improving.
  • News Sentiment

    Inovio Pharmaceuticals has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Inovio Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    27 people have searched for INO on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.30% of the stock of Inovio Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 26.79% of the stock of Inovio Pharmaceuticals is held by institutions.

  • Read more about Inovio Pharmaceuticals' insider trading history.
Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INO Stock News Headlines

The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
Q1 2025 Inovio Pharmaceuticals Inc Earnings Call
See More Headlines

INO Stock Analysis - Frequently Asked Questions

Inovio Pharmaceuticals' stock was trading at $1.83 on January 1st, 2025. Since then, INO shares have increased by 11.5% and is now trading at $2.04.
View the best growth stocks for 2025 here
.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) posted its quarterly earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.23. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.01 million.
Read the conference call transcript
.

Shares of Inovio Pharmaceuticals reverse split on the morning of Thursday, January 25th 2024.The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inovio Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

Last Earnings
5/13/2025
Today
6/30/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:INO
Employees
320
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$9.75
High Stock Price Target
$18.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+377.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$107.25 million
Pretax Margin
-34,091.52%

Debt

Sales & Book Value

Annual Sales
$220 thousand
Price / Cash Flow
N/A
Book Value
$1.90 per share
Price / Book
1.07

Miscellaneous

Free Float
35,830,000
Market Cap
$74.81 million
Optionable
Optionable
Beta
1.34

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:INO) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners